Related Experiment Video
Updated: Apr 17, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide
Jeffrey Berger1, Paula Lester2, Lucan Rodrigues3
1Divisions of Palliative Medicine and Geriatrics, Winthrop University Hospital, Mineola, NY, USA.
Background:
Malignant bowel obstruction is a highly symptomatic, often recurrent, and sometimes refractory condition in patients with intra-abdominal tumor burden. Gastro-intestinal symptoms and function may improve with anti-inflammatory, anti-secretory, and prokinetic/anti-nausea combination medical therapy.
Objective:
To describe the effect of octreotide, metoclopramide, and dexamethasone in combination on symptom burden and bowel function in patients with malignant bowel obstruction and dysfunction.
Design:
A retrospective case series of patients with malignant bowel obstruction (MBO) and malignant bowel dysfunction (MBD) treated by a palliative care consultation service with octreotide, metoclopramide, and dexamethasone. Outcomes measures were nausea, pain, and time to resumption of oral intake.
Results:
12 cases with MBO, 11 had moderate/severe nausea on presentation. 100% of these had improvement in nausea by treatment day #1. 100% of patients with moderate/severe pain improved to tolerable level by treatment day #1. The median time to resumption of oral intake was 2 days (range 1-6 days) in the 8 cases with evaluable data. Of 7 cases with MBD, 6 had For patients with malignant bowel dysfunction, of those with moderate/severe nausea. 5 of 6 had subjective improvement by day#1. Moderate/severe pain improved to tolerable levels in 5/6 by day #1. Of the 4 cases with evaluable data on resumption of PO intake, time to resume PO ranged from 1-4 days.
Conclusion:
Combination medical therapy may provide rapid improvement in symptoms associated with malignant bowel obstruction and dysfunction.
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

